VC-Backed CEVA to Acquire Controlling Stake in Chinese Animal Health Subsidiary

France-based Ceva Sante Animale S.A. said Friday that it has inked an agreement to acquire a controlling stake in Sichuan Hengtong‘s animal health subsidiary in China. No financial terms were disclosed. E. J. McKay, an investment banking firm in Shanghai, served as exclusive financial advisor to CEVA for the transaction. Based in the Sichuan Province, China, Sichuan Hengtong is a provider of powder and liquid pharmaceuticals and animal health pharmaceuticals. Spun-off from Sanofi Aventis, CEVA is an animal health group that is backed by PAI Partners, Industri Kapital, Euromezzanine and Natixis Private Equity.


LIBOURNE, France, July 19, 2013 /PRNewswire/ — Ceva Sante Animale S.A. today signed a definitive agreement to acquire a controlling stake in Sichuan Hengtong’s animal health subsidiary in China. E. J. McKay acted as the exclusive financial advisor to CEVA. The transaction will allow CEVA to significantly increase its business scope in China, especially in the chemical drug segment for animal health. Representatives from the Chinese Embassy in Paris and the French Ministry of Foreign Trade also attended the signing ceremony in Libourne, situated in the famed Bordeaux region.

“We are very pleased to have advised and represented CEVA in this transaction,” E. J. McKay CEO James Z. Li commented. “It will not only strengthen CEVA’s market-leading position worldwide, but also create a positive impact on the veterinary health industry and food security in China. This transaction also demonstrates E. J. McKay’s leadership in the pharmaceutical sector and our commitment to the France-China investment corridor.”


Headquartered in Libourne, France, CEVA is among the top 10 largest animal health groups globally, with expertise in pharmacology and biology and dedicated teams focused on the companion animal, poultry, ruminant, and swine sectors. Spun-off from Sanofi-Aventis in 1999, the company has been invested by leading investment firms PAI Partners, Industri Kapital, Euromezzanine, and Natixis Private Equity. Today, CEVA is directly present in 42 countries, with 13 research and development centers, and 21 production sites. See for more details.


Sichuan Hengtong, located in Sichuan Province, China, is a leading player in Chinese veterinary pharmaceutical market. The company has full country coverage, providing powder injection, liquid injection, powder, tablet, oral liquid, and premix animal health pharmaceuticals.


E. J. McKay is a Shanghai-based investment banking firm specialized in mergers & acquisitions, corporate finance, and wealth management. The firm has significant experience advising on the capital flows between China and Europe, the United States, Latin America, and elsewhere. Recent European transactions include SMA Technology AG’s acquisition of Jiangsu Zeversolar – the largest transaction in China’s solar industry in 2012 – as well as BMP Sunstone’s sale to Sanofi-aventis – the largest pharmaceutical transaction in China to date. E. J. McKay was also recently commissioned by the Chilean government to promote Chinese investment in Chile.